Basic Fibroblast Growth Factor Ameliorates Endothelial Dysfunction in Radiation-Induced Bladder Injury.
This study was designed to explore the effect of basic fibroblast growth factor (bFGF) on radiation-induced endothelial dysfunction and histological changes in the urinary bladder. bFGF was administrated to human umbilical vein cells (HUVEC) or urinary bladder immediately after radiation. Reduced expression of thrombomodulin (TM) was indicated in the HUVEC and urinary bladder after treatment with radiation. Decreased apoptosis was observed in HUVEC treated with bFGF. Administration of bFGF increased the expression of TM in HUVEC medium, as well as in the urinary bladder at the early and delayed phases of radiation-induced bladder injury (RIBI). At the early phase, injection of bFGF increased the thickness of urothelium and reduced inflammation within the urinary bladder. At the delayed phase, bFGF was effective in reducing fibrosis within the urinary bladder. Our results indicate that endothelial dysfunction is a prominent feature of RIBI. Administration of bFGF can ameliorate radiation-induced endothelial dysfunction in urinary bladder and preserve bladder histology at early and delayed phases of RIBI.
Department of Urology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China ; Institute of Urology, Nanjing University, Nanjing 210008, China ; Department of Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China.
Shiwei
S
Zhang
Department of Urology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China ; Institute of Urology, Nanjing University, Nanjing 210008, China ; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China.
Xuefeng
X
Qiu
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China.
Yanting
Y
Zhang
Department of Urology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China ; Institute of Urology, Nanjing University, Nanjing 210008, China ; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China.
Kai
K
Fu
Department of Urology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China ; Institute of Urology, Nanjing University, Nanjing 210008, China.
Xiaozhi
X
Zhao
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China.
Jinhui
J
Wu
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China.
Yiqiao
Y
Hu
Department of Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China.
Weiming
W
Zhu
Department of Urology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, China ; Institute of Urology, Nanjing University, Nanjing 210008, China.
Hongqian
H
Guo
D017209:Apoptosis / Q000502:physiology; D002460:Cell Line; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000473:pathology*; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D005355:Fibrosis / Q000378:metabolism / Q000473:pathology; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D011827:Radiation; D011832:Radiation Injuries / Q000378:metabolism* / Q000473:pathology; D018180:Thrombomodulin / Q000378:metabolism; D001743:Urinary Bladder / Q000378:metabolism* / Q000473:pathology; D001745:Urinary Bladder Diseases / Q000378:metabolism / Q000473:pathology
D018180:Thrombomodulin; D005346:Fibroblast Growth Factors